-$1.74 Earnings Per Share Expected for Spark Therapeutics Inc (ONCE) This Quarter
Equities analysts forecast that Spark Therapeutics Inc (NASDAQ:ONCE) will announce earnings of ($1.74) per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Spark Therapeutics’ earnings, with estimates ranging from ($2.00) to ($1.38). Spark Therapeutics reported earnings of ($1.22) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 42.6%. The firm is expected to report its next quarterly earnings report on Wednesday, February 28th.
On average, analysts expect that Spark Therapeutics will report full-year earnings of ($7.62) per share for the current financial year, with EPS estimates ranging from ($8.08) to ($7.20). For the next fiscal year, analysts anticipate that the company will post earnings of ($5.83) per share, with EPS estimates ranging from ($6.99) to ($4.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter last year, the firm earned ($1.07) EPS. The company’s revenue was up 45.8% on a year-over-year basis.
Spark Therapeutics (NASDAQ:ONCE) traded down $0.70 during midday trading on Friday, reaching $45.21. 1,524,400 shares of the company’s stock traded hands, compared to its average volume of 485,468. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.
In related news, insider Barge Joseph La sold 3,309 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $71.31, for a total value of $235,964.79. Following the completion of the sale, the insider now owns 8,146 shares in the company, valued at approximately $580,891.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Faga sold 1,500 shares of the company’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the sale, the insider now owns 1,500 shares of the company’s stock, valued at approximately $127,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,068,809 shares of company stock valued at $89,809,385 in the last 90 days. Insiders own 7.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. raised its position in Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics in the 2nd quarter valued at $143,000. Teacher Retirement System of Texas purchased a new stake in Spark Therapeutics in the 3rd quarter valued at $225,000. Prudential Financial Inc. purchased a new stake in Spark Therapeutics in the 3rd quarter valued at $239,000. Finally, Commonwealth Equity Services Inc purchased a new stake in Spark Therapeutics in the 3rd quarter valued at $257,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.